Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation. He was granted 472 shares of Common Stock in the form of restricted stock units that vest, subject to limited exceptions, on the first anniversary of the grant date. He was also granted stock options for 1,433 shares of Common Stock at an exercise price of $424.45 per share, which are fully vested and expire on April 30, 2036. Following the stock grant, he directly holds 7,344 shares of Vertex Common Stock in addition to these options.
Vertex Pharmaceuticals director Lloyd Carney received a fully vested stock option grant covering 2,866 shares of common stock. The option has an exercise price of $424.45 per share and expires on April 30, 2036. Following this award, Carney holds 2,866 stock options directly.
Vertex Pharmaceuticals director Dr. Sangeeta N. Bhatia reported two common stock transactions. She received a grant of 943 shares as a restricted stock unit award that will vest, subject to limited exceptions, on the first anniversary of the grant date. She also completed an open-market sale of 318 shares at $423.73 per share under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on 05/27/2025. After these transactions, she directly holds 4,924 shares of Vertex common stock.
Vertex Pharmaceuticals delivered strong Q1 2026 results, with total revenues of $2.99 billion, up 8% from Q1 2025. Growth was driven by continued cystic fibrosis (CF) therapies and rapid uptake of newer products ALYFTREK, CASGEVY and JOURNAVX.
Net income rose to $1.03 billion from $646.3 million, and diluted EPS increased to $4.02 from $2.49, helped by the absence of last year’s $379.0 million impairment and much lower acquired in-process R&D. Operating income nearly doubled to $1.14 billion.
R&D spending remained high at $961.6 million, while SG&A climbed 25% to $493.7 million as Vertex invests in launches like JOURNAVX and prepares povetacicept for IgA nephropathy. Cash, cash equivalents and marketable securities increased to $13.0 billion, even after $344.5 million of share repurchases in the quarter.
Vertex Pharmaceuticals reported strong first quarter 2026 results, with total revenue rising 8% to $2.99 billion versus the first quarter of 2025. Growth was driven by cystic fibrosis therapies, especially ALYFTREK, and increasing contributions from CASGEVY and JOURNAVX.
GAAP net income increased to $1.03 billion from $646.3 million, helped by higher product revenues and the absence of last year’s intangible asset impairment charge. Non-GAAP net income rose to $1.15 billion. Vertex ended March 31, 2026 with $13.0 billion in cash, cash equivalents, and marketable securities and reaffirmed full-year 2026 revenue guidance of $12.95–$13.1 billion, including at least $0.5 billion from non-CF products.
Sangeeta N. Bhatia reported a proposed sale under Rule 144 of 318 shares of common stock linked to restricted stock vesting. The filing lists a transaction date of 05/01/2026 and a reported value of $134,746.14. It also records 266 shares sold on 02/13/2026 for $133,000.00.
The shares are held at Fidelity Brokerage Services LLC and the filing indicates the underlying event was compensation (restricted stock vesting).
VRTX: A Rule 144 notice lists proposed sales of Common Stock by an affiliate, Joy Liu. The filing references a restricted stock vesting of 1,104 shares dated 02/24/2025 and reports four sales by Joy Liu between 02/12/2026 and 04/01/2026, including transactions of 9,320 and smaller lots.
Vertex Pharmaceuticals Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 19,036,076 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing discloses sole voting power for 2,523,266 shares and sole dispositive power for 19,036,076 shares. The form is signed by Ashley Grim on 04/30/2026 and includes affiliate attribution language describing managed accounts and Vanguard fund holdings.
Vertex Pharmaceuticals disclosed that director Suketu Upadhyay has decided not to stand for re-election at the company’s 2026 annual meeting of shareholders. He was recently named the forthcoming Chief Financial Officer of Incyte Corporation and cited scheduling conflicts with this new role.
Upadhyay will continue serving on the board until the 2026 annual meeting. The company stated that his decision did not involve any disagreement regarding its operations, policies, or practices. Following his departure, the board intends to reduce its size to ten members and the existing proxy materials are deemed amended to remove him from the slate of nominees, while all other nominees and previously submitted votes remain in effect.
Upadhyay Suketu reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Suketu Upadhyay received a grant of 80.508 deferred stock units on common stock, recorded at a reference price of $442.50 per unit. Following this award, he holds a total of 2,799.156 deferred stock units.
Each deferred stock unit represents one share of common stock and will be paid in stock upon the earliest of his termination from the board, a company change of control, or his disability or death. This is a compensation-related award rather than an open-market trade.